Stock listing

TPEx:4174 OBI Pharma, Inc. (浩鼎) 股價

Follow OBI Pharma, Inc. into a list and get an email when it puts out news.

Share price · TPEX:4174

$59.70 TWD +3.90 (+7.0%)

Close on Oct 14, 2026

OBI Pharma, Inc. logo
Ticker
TPEx:4174
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
TPEx
Currency
TWD

What changed lately

Latest news

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC

Jan 12, 2026

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Sep 2, 2025

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

Jun 6, 2025

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

Apr 30, 2025

OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and ThiOBI® ADC enabling technologies, the OBI-3424 prodrug, and Globo H (GH) science

Apr 22, 2025

OBI Pharma Receives ‘Most Promising ADC Clinical Candidate in Taiwan’ Award

Mar 12, 2025

OBI Pharma Enters Collaboration with GlyTech to Expand GlycOBI® Enabling Technologies Outreach in Japan and to Advance Glycan Production

Dec 23, 2024

OBI Pharma announces Phase 1/2 study initiation for OBI-992, a TROP2-targeted antibody drug-Conjugate for cancer therapy

Jun 13, 2024

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugate (ADC) for Cancer Therapy

Jun 12, 2024

OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform

Mar 18, 2024

All OBI Pharma, Inc. news

Decks

OBI Pharma, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
1 in the last 12 months · 20 in all · newest Jan 12, 2026 · oldest 2022
Decks
15 decks · latest Jun 26, 2026

Log in to ask 6ix AI your own questions about OBI Pharma, Inc.